Physician profile
Samuel J Multack
NPI 1619135233
$33,657.69
in general payments reported to CMS, 2019-2025
39 companies · $1,590 in 2025
The $1,590 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,961 · 2020: $1,545 · 2021: $9,776 · 2022: $7,736 · 2023: $6,422 · 2024: $3,628 · 2025: $1,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,426 · Food and Beverage: $4,472 · Travel and Lodging: $733 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,425.50 |
| Food and Beverage | $4,472.27 |
| Travel and Lodging | $733.47 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $27,823.86 | 2019-2025 | Argos, Ngenuity, Centurion |
| Allergan, INC. | $1,500.83 | 2019-2022 | |
| Abbvie INC. | $562.88 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $523.77 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Aerie Pharmaceuticals, INC. | $321.87 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $317.48 | 2019-2021 | |
| Rxsight INC | $269.12 | 2023-2024 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $212.65 | 2019-2025 | Tecnis Iol, Lipiflow System Activator (Disposable), Tecnis Iol |
| Mallinckrodt Hospital Products INC. | $185.92 | 2024 | Acthar |
| Sight Sciences, INC. | $174.48 | 2020-2025 | Sion Surgical Instrument, Omni Surgical System |
| Horizon Therapeutics Plc | $152.09 | 2019-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $148.55 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $121.66 | 2019 | |
| Glaukos Corporation | $114.31 | 2019-2023 | Iaccess Precision Blade, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Amgen INC. | $108.14 | 2024-2025 | Tepezza |
Show all 38 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Multack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.